Developmental funds for the next cycle are essential to our strategic plan to adopt new technology and acquire faculty expertise necessary to compliment our existing programs and advance cancer research. Moffitt proposes utilizing Developmental Funds in three categories as follows: 1) Targeted Faculty Recruitment ($200,000); 2) Pilot Projects ($100,000) and 3) Development of New Shared Resources ($100,000). During the last funding period, Moffitt benefited from developmental funds and matching institutional funds in the areas of targeted faculty recruitment and pilot projects. Moffitt invested $18.5M in support of 51 new research members over the last funding cycle, including 4 supported by Developmental Funds. Recruitment packages include a portion of salary (protected time), start-up packages, capital investments for labs, and allocation of space. Moffitt also utilized Developmental Funds with additional institutional commitment to fund pilot proposals that demonstrated a high degree of collaboration and reflected new areas of research.

Public Health Relevance

Developmental Funds play an essential role in the continued growth of the Moffitt Cancer Center by providing resources for targeted recruitment, funding innovative collaborative pilot projects and developing new shared resources to support faculty needs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-17
Application #
8815024
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-01-31
Budget Start
2015-02-01
Budget End
2016-01-31
Support Year
17
Fiscal Year
2015
Total Cost
$235,610
Indirect Cost
$95,782
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430

Showing the most recent 10 out of 1254 publications